Vertaling van "measures that have no standardized " (Nederlands → Frans) :

Despite the use of these measures by management in setting goals and measuring the Group’s performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS.
En dépit de leur importance pour la direction quand celle-ci doit fixer les objectifs et mesurer la performance du Groupe, ces mesures ne sont pas déterminées selon les normes IFRS et ne revêtent aucune des significations prescrites par lesdites normes.

Despite the importance of these measures to management in setting goals and measuring the Group’s performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS.
En dépit de leur importance pour la direction quand celle-ci doit fixer les objectifs et mesurer la performance du Groupe, ces mesures ne sont pas déterminées selon les normes IFRS et ne revêtent aucune des significations prescrites par lesdites normes.

De Queens Bench stelde dat: „The test is the standard of the ordinary skilled man exercising and professing to have that special skill ( ) the standard of care provided by a medical practioner, in law, depends upon what is done in practice‰ 91 .
Le Queens Bench a déclaré :ÿ The test is the standard of the ordinary skilled man exercising and professing to have that special skill ( ) the standard of care provided by a medical practioner, in law, depends upon what is done in practice Ÿ 91 .

" Compliance with this standard (= GCP) provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.‰
ÿ Compliance with this standard (= GCP) provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the princinciples that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. Ÿ

The revised standard requires Novartis to include in the purchase consideration the estimated amount of any contingent considerations and the measurement to fair value, through the income statement of any interest in an acquired company that had been previously held.
Celle-ci requiert de Novartis d’inclure dans le prix d’acquisition le montant estimé de toute contrepartie éventuelle et d’évaluer à la juste valeur par le compte de résultat tout intérêt dans une entreprise acquise qui a été détenue précédemment.

If investigation and follow-up on the initial causes of the incident prove necessary, the processing of the case must take no more than one month, naturally after the first urgent and necessary measures have been taken.
If investigation and follow-up on the initial causes of the incident prove necessary, the processing of the case must take no more than one month, naturally after the first urgent and necessary measures have been taken.

However, if a medicine is being administered for which there is no MA, a minimum number of quality standards need to be put in place and a minimum guarantee needs to be provided through the animal tests conducted or existing experience with humans, suggesting that the
However, if a medicine is being administered for which there is no MA, a minimum number of quality standards need to be put in place and a minimum guarantee needs to be provided through the animal tests conducted or existing experience with humans, suggesting that the

“In any case, our observations have no doubt a great social value: in spite of the fact that Belgium has a widespread offer of medical care for emotional problems and mental disorders, it is clear from the ESEMeD data that the resources are not used optimally.
« En tout cas, nos observations ont sans conteste une grande valeur sociale: malgré le fait que la Belgique dispose d’une importante offre de soins pour les problèmes émotionnels et les troubles mentaux, les données ESEMeD révèlent que les ressources ne sont pas utilisées de manière optimale.

Famvir litigation In February 2010, Novartis and Teva have reached a settlement ending the US patent litigation between them relating to Famvir, a therapy for viral infections, after a trial against Teva in November 2009 resulted in a jury verdict in favor of Novartis that the compound patent was valid and enforceable and an advisory verdict that there was no inequitable conduct.
Litige portant sur Famvir En février 2010, Novartis et Teva sont parvenus à un règlement mettant fin au litige sur le brevet américain qui les opposait dans le cas de Famvir, un traitement des infections virales. Un procès contre Teva, qui s’est terminé en novembre 2009 par un verdict du jury en faveur de Novartis, a conclu que le brevet de la molécule était valide et exécutoire et par un verdict consultatif confirmant que la conduite de la société n’avait pas été inéquitable.

If no comments have been received within this timeframe, it is tacitly assumed that the FAMHP has approved the commencement of the clinical trial.
If no comments have been received within this timeframe, it is tacitly assumed that the FAMHP has approved the commencement of the clinical trial.